1 Magnificent Dividend Growth Stock That's Down 40% and Trading at a Once-in-a-Decade Valuation
So far, 2024 has been a year to forget for animal healthcare juggernaut (NYSE: ZTS). Hit by the triple whammy of weak earnings, a formal investigation from the European Commission, and adverse events linked to some of its newest medicines, Zoetis has seen its share price plunge 27% this year and 40% from its all-time highs.
We will get to these issues in a moment, but the silver lining to these recent developments is that Zoetis shares now trade at a once-in-a-decade valuation. So this begs the question: Is Zoetis now a fundamentally flawed business destined to continue dropping? Or is this sell-off a unique opportunity for investors willing to buy and hold for a decade and beyond?
Here's why I'm leaning toward the latter.
Source Fool.com
Zoetis Inc. A Aktie
170,66 €
1,79 %
Überwältigendes Buy-Interesse bei Zoetis Inc. A, mit einer hohen Anzahl von Buy- und wenigen Sell-Einschätzungen.
Für Zoetis Inc. A ergibt sich ein leicht positives Potenzial, angesichts eines Kursziels von 196 € im Vergleich zu 170.66 €.
